BARCELONA Sun Aug 31, 2014 12:49pm EDT
The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.
Credit: Reuters/Arnd Wiegmann
<span id="articleText"/>BARCELONA (Reuters) - The expected launch of Novartis's new heart failure drug next year promises to be the company's most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday.
<span id="midArticle_0"/>The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
<span id="midArticle_1"/>Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multibillion-dollar sales opportunity.
<span id="midArticle_2"/>"It will be possibly the most exciting launch the company has ever had," David Epstein told an investor meeting.
<span id="midArticle_3"/>The profitability of the drug would also be higher than Novartis achieved when its blockbuster hypertension medicine Diovan was still patent-protected, since the cost of marketing LCZ696 will be lower. That reflects the more specialized nature of heart failure, which requires a smaller sales force.
<span id="midArticle_4"/>As a result, LCZ696 should become profitable relatively quickly, though Novartis will be investing to ensure a strong launch. Epstein said he did not expect any increase in the overall sales force because staff would be switched from promoting some older drugs.
<span id="midArticle_5"/>In a research note issued by investment bank Leerink on the back of the strong trial results, analyst Seamus Fernandez said that LCZ696 could rack up annual sales of $6-8 billion, with further upside in emerging markets and from new indications.
<span id="midArticle_6"/>The study unveiled in Barcelona targeted heart patients with reduced ejection fraction, where the heart muscle does not contract effectively. However, Novartis is also starting a trial in a similar-sized group with preserved ejection fraction, where the ventricles do not relax as they should.
<span id="midArticle_7"/><span id="midArticle_8"/>(Reporting by Ben Hirschler; Editing by David Goodman)
<span id="midArticle_9"/>
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://ift.tt/NWKAHy
<a name="comments"/>Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.
- Tweet<li class="c4"/><li class="linkedIn" tns="no"/>
- Share this
- <span id="googleTag"/>
Credit: Reuters/Arnd Wiegmann
<span id="articleText"/>BARCELONA (Reuters) - The expected launch of Novartis's new heart failure drug next year promises to be the company's most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday.
<span id="midArticle_0"/>The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.
<span id="midArticle_1"/>Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multibillion-dollar sales opportunity.
<span id="midArticle_2"/>"It will be possibly the most exciting launch the company has ever had," David Epstein told an investor meeting.
<span id="midArticle_3"/>The profitability of the drug would also be higher than Novartis achieved when its blockbuster hypertension medicine Diovan was still patent-protected, since the cost of marketing LCZ696 will be lower. That reflects the more specialized nature of heart failure, which requires a smaller sales force.
<span id="midArticle_4"/>As a result, LCZ696 should become profitable relatively quickly, though Novartis will be investing to ensure a strong launch. Epstein said he did not expect any increase in the overall sales force because staff would be switched from promoting some older drugs.
<span id="midArticle_5"/>In a research note issued by investment bank Leerink on the back of the strong trial results, analyst Seamus Fernandez said that LCZ696 could rack up annual sales of $6-8 billion, with further upside in emerging markets and from new indications.
<span id="midArticle_6"/>The study unveiled in Barcelona targeted heart patients with reduced ejection fraction, where the heart muscle does not contract effectively. However, Novartis is also starting a trial in a similar-sized group with preserved ejection fraction, where the ventricles do not relax as they should.
<span id="midArticle_7"/><span id="midArticle_8"/>(Reporting by Ben Hirschler; Editing by David Goodman)
<span id="midArticle_9"/>
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://ift.tt/NWKAHy
<a name="comments"/>Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.
via Smart Health Shop Forum http://ift.tt/1tmbmPr
No comments:
Post a Comment